Article
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Chapter title |
Vaccine Development for Epstein-Barr Virus
|
|---|---|
| Chapter number | 22 |
| Book title |
Human Herpesviruses
|
| Published in |
Advances in experimental medicine and biology, January 2018
|
| DOI | 10.1007/978-981-10-7230-7_22 |
| Pubmed ID | |
| Book ISBNs |
978-9-81-107229-1, 978-9-81-107230-7
|
| Authors |
Jeffrey I. Cohen, Cohen, Jeffrey I. |
| Abstract |
Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis and is associated with several malignancies, including nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, Burkitt lymphoma, and lymphomas in immunocompromised persons, as well as multiple sclerosis. A vaccine is currently unavailable. While monomeric EBV gp350 was shown in a phase 2 trial to reduce the incidence of infectious mononucleosis, but not the rate of EBV infection, newer formulations of gp350 including multimeric forms, viruslike particles, and nanoparticles may be more effective. A vaccine that also includes additional viral glycoproteins, lytic proteins, or latency proteins might improve the effectiveness of an EBV gp350 vaccine. Clinical trials to determine if an EBV vaccine can reduce the rate of infectious mononucleosis or posttransplant lymphoproliferative disease should be performed. The former is important since infectious mononucleosis can be associated with debilitating fatigue as well as other complications, and EBV infectious mononucleosis is associated with increased rates of Hodgkin lymphoma and multiple sclerosis. A vaccine to reduce EBV posttransplant lymphoproliferative disease would be an important proof of principle to prevent an EBV-associated malignancy. Trials of an EBV vaccine to reduce the incidence of Hodgkin lymphoma, multiple sclerosis, or Burkitt lymphoma would be difficult but feasible. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 33% |
| Spain | 2 | 13% |
| United Kingdom | 1 | 7% |
| Serbia | 1 | 7% |
| Unknown | 6 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 67% |
| Scientists | 3 | 20% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 156 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 35 | 22% |
| Student > Master | 16 | 10% |
| Researcher | 14 | 9% |
| Student > Ph. D. Student | 11 | 7% |
| Student > Doctoral Student | 8 | 5% |
| Other | 19 | 12% |
| Unknown | 53 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 26 | 17% |
| Medicine and Dentistry | 23 | 15% |
| Immunology and Microbiology | 13 | 8% |
| Agricultural and Biological Sciences | 11 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Other | 22 | 14% |
| Unknown | 56 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2024.
All research outputs
#2,050,814
of 25,805,386 outputs
Outputs from Advances in experimental medicine and biology
#291
of 5,279 outputs
Outputs of similar age
#45,055
of 452,369 outputs
Outputs of similar age from Advances in experimental medicine and biology
#6
of 243 outputs
Altmetric has tracked 25,805,386 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,279 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,369 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 243 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.